Imagen de Portada

Body composition and plasma total‐tau, neurofilament light chain, and amyloid‐β: A population‐based study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Tosca O. E. de Crom, Mohsen Ghanbari, Trudy Voortman, M. Arfan Ikram
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Association of plasma neurofilament light chain with microstructural white matter changes in Down syndrome
por: Herminia Diana Rosas, et al.
Publicado: (2024)

Clinical and neuropathological associations of plasma Aβ42/Aβ40, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders
por: Binita Rajbanshi, et al.
Publicado: (2025)

Cross‐sectional study of plasma phosphorylated tau 217 in persons without dementia
por: Toni T. Saari, et al.
Publicado: (2025)

Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
por: Kazuki Yamada, et al.
Publicado: (2026)

Diagnostic utility of plasma p‐tau217 differs by Alzheimer's disease tau‐based subtypes
por: Seyed Hani Hojjati, et al.
Publicado: (2025)

Hallucinations and delusions are associated with elevated tau PET signal independent of age, clinical severity, and amyloid burden
por: Aubrey S Johnson, et al.
Publicado: (2026)

Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease
por: Soheil Mohammadi, et al.
Publicado: (2025)

Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
por: Qi Huang, et al.
Publicado: (2025)

Investigating the amyloid–tau–neurodegeneration framework in Alzheimer's disease using semi‐supervised multimodal imaging data fusion
por: You Cheng, et al.
Publicado: (2026)

Clinical and demographic factors modify the association between plasma phosphorylated tau‐181 and cognition
por: Corey J. Bolton, et al.
Publicado: (2024)

Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting
por: Rebecca Z. Rousset, et al.
Publicado: (2024)

Characterizing Japanese older adults without dementia by amyloid PET status: A comparative study of amyloid‐positive and amyloid‐negative groups from Japanese trial‐ready cohort study
por: Saki Nakashima, et al.
Publicado: (2026)

Comparison of three plasma p‐tau217 assays to detect PET‐confirmed Alzheimer's pathologies
por: Sayo Matsuura, et al.
Publicado: (2026)

Associations of plasma phosphorylated tau217 with cognitive impairment and brain microstructural alterations in Alzheimer's disease
por: Miguel Ángel Rivas‐Fernández, et al.
Publicado: (2026)

Social relationships, amyloid burden, and dementia: The ARIC‐PET study
por: Renée C. Groechel, et al.
Publicado: (2024)

Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples
por: Anna E. Mammel, et al.
Publicado: (2025)

Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohort
por: Joyce R. Chong, et al.
Publicado: (2024)

Eligibility for anti‐amyloid treatment in a multiethnic community‐based study
por: Lydia Trudel, et al.
Publicado: (2026)

Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
por: Adam H. Dyer, et al.
Publicado: (2025)

Plasma amyloid‐β oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer's dementia: Findings from the GMCII cohort
por: Yuhan Xie, et al.
Publicado: (2025)

Deep medullary vein abnormalities associated with cognitive function and Alzheimer's disease plasma biomarkers in dementia‐free older adults: A population‐based study
por: Dejia Yin, et al.
Publicado: (2026)

Intracranial arteriosclerosis is not associated with cerebral amyloid deposition
por: Anna M. Streiber, et al.
Publicado: (2024)

Standardization of criteria in MacCAT‐T and MacCAT‐CR for monoclonal anti–beta‐amyloid antibodies: A Delphi study
por: Jonas Karneboge, et al.
Publicado: (2025)

Development of amyloid‐negative neuropsychological norms using GAMLSS
por: Sara Rubio‐Guerra, et al.
Publicado: (2025)

Factors associated with discordant visual and quantitative amyloid PET results
por: Jasmin E Guevara, et al.
Publicado: (2026)

Input of exome sequencing in early‐onset cerebral amyloid angiopathy
por: Lou Grangeon, et al.
Publicado: (2024)

Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
por: Annibale Antonioni, et al.
Publicado: (2025)

P‐tau217 testing impact on intended management of patients presenting with cognitive impairment: A randomized clinical utility study
por: Samantha C. Burnham, et al.
Publicado: (2025)

Neurofilament light chain concentration mediates the association between regional medial temporal lobe structure and memory in adults with Down syndrome
por: Natalie DiProspero, et al.
Publicado: (2024)

Patients’ choices and eligibility for anti‐amyloid therapy in Japan's universal insurance
por: Ryoko Ihara, et al.
Publicado: (2026)

Motor, not cognitive, performance relates to amyloid status in normal older adults
por: Amanda Cook Maher, et al.
Publicado: (2026)

White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
por: Antoine Garnier‐Crussard, et al.
Publicado: (2026)

Faster decline of very prodromal dementia with Lewy bodies when amyloid positive
por: Frédéric Blanc, et al.
Publicado: (2025)

Multi‐modal machine learning for predicting amyloid positivity using on‐ramp driving
por: Sai Santosh Reddy Danda, et al.
Publicado: (2025)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
por: Cassandra Marotta, et al.
Publicado: (2025)

Survey among experts on the future role of tau‐PET in clinical practice and trials
por: Marie R. Vermeiren, et al.
Publicado: (2024)

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET‐MR
por: Hossein Moein Taghavi, et al.
Publicado: (2024)

Identifying cognitive test scores associated with early tau burden in Alzheimer's disease
por: Caitlin M. Terao, et al.
Publicado: (2025)

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
por: Lara Blömeke, et al.
Publicado: (2024)

sTREM2 in discordant CSF Aβ42 and p‐tau181
por: Danni Li, et al.
Publicado: (2025)